Research programme: endomorphin analogues - Cytogel Pharma

Drug Profile

Research programme: endomorphin analogues - Cytogel Pharma

Alternative Names: EM-1; Endomorphin-1

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tulane University
  • Developer Cytogel
  • Class Analgesics; Peptides
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 11 Sep 2018 Tulane University has patent protection for endomorphin (EM-1) and related species (Cytogel Pharma website, September 2018)
  • 07 Sep 2018 Preclinical development is ongoing in the US
  • 07 Sep 2018 Research programme: endomorphin analogues - Cytogel Pharma is available for licensing as of 07 Sep 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top